众生药业：ZSP1601片为国家重大新药创制项目，该项目正在开展IIb期临床试验

Core Viewpoint - The company is actively developing ZSP-1601, an innovative drug for treating metabolic dysfunction-related fatty liver disease (MASH), currently in Phase IIb clinical trials [2] Group 1: Drug Development - ZSP-1601 is characterized by a novel mechanism of action and is part of a major national new drug creation project [2] - The company is focused on the progress of ZSP-1601 and is committed to transparency regarding its clinical advancements [2] Group 2: International Collaboration - The company is seeking international cooperation opportunities for ZSP-1601 and is open to discussions with foreign companies for business development [2] - The company emphasizes its commitment to timely information disclosure in accordance with relevant regulations if certain disclosure standards are met [2]